相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J. Pietzak et al.
EUROPEAN UROLOGY (2017)
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Lian Dee Ler et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency
Carolyn D. Hurst et al.
CANCER CELL (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA
Leslie C. Sutherland et al.
BMC MOLECULAR BIOLOGY (2017)
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
Jakob Hedegaard et al.
CANCER CELL (2016)
Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
Philippe Lamy et al.
CANCER RESEARCH (2016)
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Jaegil Kim et al.
NATURE GENETICS (2016)
Genomic characterization of high-risk non-muscle invasive bladder cancer
Joshua J. Meeks et al.
ONCOTARGET (2016)
Cohesin Mutations in Cancer
Magali De Koninck et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Determining the origin of synchronous multifocal bladder cancer by exome sequencing
Omer Acar et al.
BMC CANCER (2015)
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer
Ismail Hosen et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma
Joshua I. Warrick et al.
VIRCHOWS ARCHIV (2015)
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
Yves Allory et al.
EUROPEAN UROLOGY (2014)
Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine
Carolyn D. Hurst et al.
EUROPEAN UROLOGY (2014)
Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes
Claire F. Taylor et al.
HUMAN MOLECULAR GENETICS (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer
Iver Nordentoft et al.
CELL REPORTS (2014)
Differential Binding of RhoA, RhoB, and RhoC to Protein Kinase C-Related Kinase (PRK) Isoforms PRK1, PRK2, and PRK3: PRKs Have the Highest Affinity for RhoB
Catherine L. Hutchinson et al.
BIOCHEMISTRY (2013)
TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
Isaac Kinde et al.
CANCER RESEARCH (2013)
Oncogenic FGFR3 gene fusions in bladder cancer
Sarah V. Williams et al.
HUMAN MOLECULAR GENETICS (2013)
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Guangwu Guo et al.
NATURE GENETICS (2013)
Frequent truncating mutations of STAG2 in bladder cancer
David A. Solomon et al.
NATURE GENETICS (2013)
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
Cristina Balbas-Martinez et al.
NATURE GENETICS (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value
Yvonne Chekaluk et al.
PLOS ONE (2013)
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
P. Sivaramakrishna Rachakonda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Carolyn D. Hurst et al.
CLINICAL CANCER RESEARCH (2012)
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma
Sandra Rebouissou et al.
JOURNAL OF PATHOLOGY (2012)
The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles
Mattias Hoglund
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
The loss of 8p23.3 is a novel marker for predicting progression and recurrence of bladder tumors without muscle invasion
Satoshi Eguchi et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Fiona M. Platt et al.
CLINICAL CANCER RESEARCH (2009)
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
Louis S. Pymar et al.
HUMAN MOLECULAR GENETICS (2008)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
The p53 pathway and outcome among patients with T1G3 bladder tumors
Elena Lopez-Knowles et al.
CLINICAL CANCER RESEARCH (2006)
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors
Elena Lopez-knowles et al.
CANCER RESEARCH (2006)
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
Silvia Hernandez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bladder cancer stage and outcome by array-based comparative genomic hybridization
E Blaveri et al.
CLINICAL CANCER RESEARCH (2005)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma
S Krüger et al.
EUROPEAN UROLOGY (2005)
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer
R Stoehr et al.
LABORATORY INVESTIGATION (2004)
p53 mutations in urinary bladder cancer
P Berggren et al.
BRITISH JOURNAL OF CANCER (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
